The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
Daniel Keizman
No relevant relationships to disclose
Maya Ish-Shalom
No relevant relationships to disclose
Jason David Taksey
No relevant relationships to disclose
Roberto Pili
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Ben Boursi
No relevant relationships to disclose
Raanan Berger
No relevant relationships to disclose
Natalie Maimon
No relevant relationships to disclose
Maya Gottfried
No relevant relationships to disclose
Henry Hayat
No relevant relationships to disclose
Avivit Peer
No relevant relationships to disclose
Svetlana Kovel
No relevant relationships to disclose
Avishay Sella
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose